エピソード

  • ,000 Silent Deaths: Why Malpractice Cases Vanish in Hospitals

    ,000 Silent Deaths: Why Malpractice Cases Vanish in Hospitals
    2026/07/26
    ,000 Silent Deaths: Why Malpractice Cases Vanish in Hospitals

    Four hundred thousand preventable hospital deaths occur in the U.S. every year, while only seventeen thousand malpractice claims are filed - leaving roughly three hundred and eighty-three thousand deaths without legal action. How did a system emerge that filters out so many grieving families before they even reach a courtroom?

    In this episode, we trace the gap between documented preventable deaths and filed claims, showing what families must prove to bring a malpractice case and why decades of reforms have failed to narrow that gap. What exactly are the five legal elements that keep most cases from ever being litigated?

    Person: John T. James, PhD
    Date: 1984 estimate and 2008 cost analysis
    Event: First systemic estimate of preventable hospital deaths
    Topic: Five legal elements required for malpractice claims
    Country: United States

    - Estimate in 1984: between 44,000 and 98,000 preventable hospital deaths per year
    - Later analysis by John T. James, PhD: 400,000 preventable hospital deaths annually
    - CDC estimate: 75,000 annual deaths from hospital-acquired infections
    - Medicare data (2000-2002): 1.14 million patient-safety incidents among beneficiaries
    - Filed malpractice claims per year: 17,000 compared with approximately 400,000 preventable deaths

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    19 分
  • ,000 Dead, 17,000 Lawsuits: Why Justice Fails Hospital Victims

    ,000 Dead, 17,000 Lawsuits: Why Justice Fails Hospital Victims
    2026/07/25
    ,000 Dead, 17,000 Lawsuits: Why Justice Fails Hospital Victims

    Nearly 400,000 Americans die in hospitals each year from preventable errors, while only about 17,000 malpractice lawsuits are filed annually-what stops grieving families from reaching a courtroom? How can a system meant to deliver accountability and compensation allow such a gap to persist?

    In this episode, we lay out the evidence and narratives that trace the gap between patient harm and legal redress, from landmark studies in 1984 to Medicare and CDC data in the early 2000s, and ask what structural features of the medical liability system produce this outcome.

    Person: John T. James, PhD
    Date: 1984 study cited; Medicare data from 2000-2002; October 2008 cost analysis
    Event: Estimated 400,000 preventable hospital deaths per year
    Case: Approximately 17,000 malpractice lawsuits filed per year

    - 400,000 is the estimated number of unnecessary deaths inside American hospitals per year, according to John T. James.
    - 17,000 is the approximate number of medical malpractice lawsuits filed across the United States in the same year.
    - 44,000-98,000 was the 1984 estimated annual deaths from preventable hospital errors reported in the medical literature.
    - 1.14 million patient-safety incidents were recorded in Medicare data across 37 million hospitalizations between 2000 and 2002.
    - 75,000 patients were estimated by the CDC to die annually from hospital-acquired infections.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    21 分
  • ,000 Silent Deaths: How Hospitals Hide Preventable Patient Killings

    ,000 Silent Deaths: How Hospitals Hide Preventable Patient Killings
    2026/07/24
    ,000 Silent Deaths: How Hospitals Hide Preventable Patient Killings

    More Americans die each year inside hospitals from preventable errors than from stroke or diabetes - a peer‑reviewed estimate puts the toll at 400,000 - yet only about 17,000 malpractice lawsuits are processed annually; how can a system that costs billions fail to account for most of these deaths?

    In this episode, we lay out the data behind estimates of preventable hospital deaths, track how those numbers changed from 1984 to the 2000s, and explain the legal architecture that often leaves documented negligence without remedy; what explains the gap between the scale of harm and the number of cases pursued?

    Person: John T. James
    Topic: Preventable hospital deaths
    Date: 1984-2004 (studies cited across these years)
    Event: 17,000 malpractice lawsuits processed per year
    Estimate: 400,000 annual deaths (peer‑reviewed aggregation)

    - 400,000 annual deaths is John T. James’s peer‑reviewed estimate of preventable deaths inside American hospitals.
    - 17,000 malpractice lawsuits are processed in the United States each year, according to the transcript.
    - The CDC’s figure for hospital deaths from infections is 75,000, a smaller, more narrowly defined count.
    - A 1984 study originally estimated between 44,000 and 98,000 annual hospital deaths from medical errors.
    - One third of malpractice claims in a 2013 BMJ Open study involve failure to diagnose, with death being the most common outcome.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    18 分
  • ,000 Preventable Hospital Deaths - Why Only 17,000 Sued?

    ,000 Preventable Hospital Deaths - Why Only 17,000 Sued?
    2026/07/23
    ,000 Preventable Hospital Deaths - Why Only 17,000 Sued?

    Four hundred thousand preventable hospital deaths occur every year in the United States, yet courts see only seventeen thousand medical malpractice claims in the same period - a gap that exposes how ordinary acts like a missed diagnosis become legally invisible. How can routine errors that researchers traced for decades translate into so few lawsuits?

    In this episode, we lay out the scale of preventable harm documented by researchers from 1984 onward and explain the legal requirements that filter most cases out of court, asking why the architecture of tort law leaves so many deaths unaddressed.

    Person: John T. James
    Date: 1984
    Topic: Preventable hospital deaths
    Event: Journal of Patient Safety publication
    Country: United States

    - John T. James published an analysis in the Journal of Patient Safety estimating 400,000 preventable hospital deaths per year.
    - A 1984 study estimated between 44,000 and 98,000 preventable deaths annually.
    - The CDC found 75,000 deaths per year from hospital-acquired infections alone.
    - Researchers using Medicare data identified 1.14 million adverse incidents across 37 million hospitalizations.
    - Approximately 17,000 medical malpractice claims are recorded annually in American courts, not all resulting in compensation.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    18 分
  • ,000 Dead, 17,000 Lawsuits: America's Invisible Medical Justice Gap

    ,000 Dead, 17,000 Lawsuits: America's Invisible Medical Justice Gap
    2026/07/22
    ,000 Dead, 17,000 Lawsuits: America's Invisible Medical Justice Gap

    Four hundred thousand people die in American hospitals every year from preventable causes, yet only seventeen thousand malpractice lawsuits are filed annually - a gap of 383,000 deaths with no legal reckoning. How can peer-reviewed science, CDC infection tallies, and documented patient-safety incidents coexist with a legal system that processes so few claims?

    In this episode, we lay out the data and the system that produces that discrepancy, drawing on peer-reviewed research by John T. James, CDC figures, and large-sample Medicare analyses to ask why the law captures so little of the harm: is it procedural barriers, evidence rules, or something else?

    Person: John T. James, PhD
    Date: October 2008 (one-month hospital error cost study)
    Period: 1984-2010s (history of patient-safety estimates)
    Event: CDC documented 75,000 hospital-acquired infection deaths per year
    Case: 2000-2002 study of 37 million Medicare hospitalizations identifying 1.14 million patient-safety incidents

    - Peer-reviewed estimate: 400,000 preventable hospital deaths per year (John T. James)
    - Lawsuits filed: approximately 17,000 malpractice claims per year nationwide
    - One-month cost: $324,000,000 in additional hospital costs from medical errors (October 2008)
    - CDC figure: 75,000 deaths per year from hospital-acquired infections alone
    - Medicare study: 1.14 million patient-safety incidents found in 37 million hospitalizations (2000-2002)

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    20 分
  • Midnight Collapse: How Simufilam's Science Vanished and Patients Waited

    Midnight Collapse: How Simufilam's Science Vanished and Patients Waited
    2026/07/22
    Midnight Collapse: How Simufilam's Science Vanished and Patients Waited

    There is a slow-motion intellectual horror in this story: a drug tested by hundreds of Alzheimer's patients rested almost entirely on data from one lab, and by November 25, 2024 the Phase III trials had failed and simufilam was declared dead - but the original data was never produced. How did a molecule called simufilam and a protein called filamin A come to carry sixteen million dollars of public research investment, only to evaporate alongside a criminal case dropped at midnight?

    In this episode, we trace the arc from laboratory claims to clinical trials and a midnight legal collapse. We lay out how a single research program shaped a company's entire strategy, how co-authorship linked academia to industry, and why investigators kept finding the same missing piece: no underlying data. What does it mean for patients and science when the foundation cannot be verified?

    Person: Hoau-Yan Wang
    Person: Lindsay Burns
    Company: Cassava Sciences
    Event: Phase III trials failed and simufilam discontinued
    Date: November 25, 2024

    - Simufilam (PTI-125) was named by the United States Adopted Names council in August 2020.
    - More than hundreds of patients enrolled in open-label studies beginning March 2020.
    - The foundational mechanism was described in two papers published in 2012 (Journal of Neuroscience) and 2017 (Neurobiology of Aging).
    - The NIH granted Cassava Sciences funding in 2018 to pursue early clinical trials.
    - Sixteen million dollars in public research funds were connected to the work centered on filamin A.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    20 分
  • Where Did the Simufilam Data Vanish? The Filamin A Mystery

    Where Did the Simufilam Data Vanish? The Filamin A Mystery
    2026/07/22
    Where Did the Simufilam Data Vanish? The Filamin A Mystery

    Hope for months of life was funded with sixteen million dollars in federal grants-yet investigators later found zero original data to support the mechanism behind simufilam. How did a drug program that enrolled hundreds, sparked four simultaneous investigations, and ended with the announcement “the drug did not work” come to rest on no surviving primary records?

    In this episode, we tell the story of the filamin A hypothesis and the simufilam program, tracing how a single laboratory’s data became the foundation for clinical trials and multimillion-dollar NIH funding. What exactly vanished from the record, and what does that mean for the patients and science that relied on it?

    Person: Hoau-Yan Wang
    Person: Lindsay Burns
    Institution: City University of New York (CUNY)
    Company: Pain Therapeutics / Cassava Sciences
    Amount: $16,000,000

    - The NIH funding related to this program totaled sixteen million dollars.
    - The filamin A mechanism was primarily reported by one lab led by Hoau-Yan Wang.
    - Foundational papers on filamin A’s role were published in 2008 and 2009 in PLOS One.
    - By March 2020 Cassava Sciences launched open-label studies of simufilam with enrolled patients.
    - The program ended on November 25, 2024 with the announcement that the drug did not work.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    19 分
  • 0.5 mg "sic" vs 400 mg aspirin; compound unnamed; human stakes: potential psychedelic/antidepressant but unconfirmed

    0.5 mg "sic" vs 400 mg aspirin; compound unnamed; human stakes: potential psychedelic/antidepressant but unconfirmed
    2026/07/22
    0.5 mg "sic" vs 400 mg aspirin; compound unnamed; human stakes: potential psychedelic/antidepressant but unconfirmed

    A single line in a paper flagged with a Latin mark calls out an impossible dose: half a milligram - one-eightieth the weight of an aspirin - and that unexplained number has haunted six decades of research into a drug that made rodents act like they'd taken LSD. How did a molecule that produced clear psychedelic-like effects in animals, yet caused uncontrollable vomiting and produced no psychedelic reports in humans at 25 mg, remain a pharmacological ghost in the literature?

    In this episode, we trace the molecule’s arc from its first synthesis in 1966 through animal studies, receptor mapping, and the sparse human data, and we ask what stalled its path to clinical clarity - is the answer buried in an embargoed doctoral thesis or in the messy biology of serotonin receptors?

    Person: quipazine
    Date: first reported 1966
    Event: registered head-twitch response in rodents by 1977
    Dose reported in human volunteers: 25 mg orally with nausea and no LSD-like effects
    Embargoed record: doctoral thesis at Columbia University embargoed until 2030

    - The paper lists a dose of 0.5 mg, annotated with a Latin mark indicating doubt.
    - Quipazine was first synthesized and reported in 1966.
    - By 1977, quipazine produced the head-twitch response in rodents, a marker of 5-HT2A activation.
    - Human volunteers given 25 mg orally reported nausea, flatulence, gastrointestinal discomfort, and diarrhea with no psychedelic subjective effects.
    - A 1994 theoretical proposal suggested an anti-nausea drug could enable human testing, but the proposed test appears only in an anonymous, unverified report and a Columbia thesis embargoed until 2030.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    20 分